ESTRO 2025 - Abstract Book

S661

Clinical - CNS

ESTRO 2025

Conclusion: BNCT improves post-recurrence survival in patients with recurrent glioblastoma, whereas no significant survival benefit was observed for recurrent grade 4 IDH mutated gliomas.

Keywords: Boron neutron capture therapy, glioblastoma

References: [1] Miyatake S-I, Wanibuchi M, Hu N, Ono K. Boron neutron capture therapy for malignant brain tumors. Journal of neuro-oncology. 2020; 149:1-11. [2] Furuse M, Kawabata S, Wanibuchi M, et al. Boron neutron capture therapy and add-on bevacizumab in patients with recurrent malignant glioma. Japanese Journal of Clinical Oncology. 2022; 52(5):433-440.

558

Digital Poster Impact of gamma knife radiosurgery dose-rate on patient outcomes: a systematic review and meta-analysis Jane Jomy 1,2 , Ke Xin Lin 2 , Radha Sharma 2 , Rachel Lu 2 , Sanchit Kaushal 2 , Anna T Santiago 3 , Dana Keilty 1 , David Shultz 1 , Catherine Coolens 1 , Michael D Cusimano 4 , Gelareh Zadeh 5 , Mojgan Hodaie 5 , Suneil K Kalia 5 , Farshad Nassiri 5 , Ying Meng 6 , Derek S Tsang 1 , Michael Yan 1 1 Radiation Medicine Program, University Health Network, Toronto, Canada. 2 Temerty Faculty of Medicine, University of Toronto, Toronto, Canada. 3 Department of Biostatistics, University Health Network, Toronto, Canada. 4 Division of Neurosurgery, Unity Health Toronto, Toronto, Canada. 5 Division of Neurosurgery, University Health Network, Toronto, Canada. 6 Division of Neurosurgery, Sunnybrook Health Sciences Centre, Toronto, Canada Purpose/Objective: Gamma knife radiosurgery (GKRS) is an effective treatment modality in the treatment of trigeminal neuralgia (TN), benign and malignant brain tumors, and other intracranial targets. However, the impact of dose-rate on clinical outcomes is not well characterized. This systematic review and meta-analysis aims to evaluate the effect of GKRS dose-rate on managing intracranial targets. Material/Methods: We searched MEDLINE, Embase, PsycInfo, and Web of Science from inception to May 2024, for studies that report on the impact of GKRS dose-rate on patient outcomes for any intracranial target. Random-effects meta-analyses